-
April 30, 2013
GlaxoSmithKline has returned the rights to the investigational Parkinson's disease drug Rytary to partner Impax Laboratories, citing regulatory delays
Full story
-
March 12, 2013
Eyebrows have been raised after Astellas Pharma decided to end its collaboration with Ambit Biosciences Corp to develop the latter's acute myeloid leukaemia treatment quizartinib
Full story
-
March 11, 2013
Galapagos have suffered a setback with partner Roche ending a partnership with the Belgian biotech which focused on fibrosis
Full story
-
November 09, 2012
GlaxoSmithKline and XenoPort have settled their dispute over Horizant in a move that will see the UK major return the rights to the restless legs syndrome drug
Full story
-
May 08, 2012
Shares in Roche have taken a bashing after the Swiss major has pulled the plug on dalcetrapib, a drug which raises 'good' cholesterol, after suffering a late-stage study failure
Full story
-
February 15, 2012
Sweden's Karo Bio has pulled the plug on its late-stage cholesterol compound eprotirome and abandoned plans to spin off its preclinical operations
Full story
-
February 01, 2012
Sweden's Orexo has suffered a setback on the news that Johnson & Johnson has terminated the firms' anti-inflammatory collaboration
Full story
-
January 17, 2012
GlaxoSmithKline is taking full control of a cancer drug discovery collaboration from Astex Pharmaceuticals
Full story
-
January 08, 2012
Astellas Pharma has terminated its global licensing agreement with Theravance to co-market the latter's superbug antibiotic Vibativ, which has been hit by manufacturing problems
Full story
-
November 08, 2011
They have been together since 2002 but Amylin and Eli Lilly are now dissolving their pact for the diabetes drugs Byetta and Bydureon in an agreement that could cost the former firm well over $1 billion
Full story